hVIVO plc Stock

Equities

VENN

GB00B9275X97

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:03 2024-04-17 am EDT 5-day change 1st Jan Change
27.6 GBX +1.47% Intraday chart for hVIVO plc -4.83% +16.21%
Sales 2023 56.04M 69.81M Sales 2024 * 62.07M 77.31M Capitalization 188M 234M
Net income 2023 16M 19.93M Net income 2024 * 9M 11.21M EV / Sales 2023 2.88 x
Net cash position 2023 * 34.79M 43.34M Net cash position 2024 * 41.48M 51.67M EV / Sales 2024 * 2.36 x
P/E ratio 2023
10.1 x
P/E ratio 2024 *
21.8 x
Employees 274
Yield 2023 *
1.47%
Yield 2024 *
0.84%
Free-Float 60.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.47%
1 week-4.17%
Current month-6.44%
1 month-3.16%
3 months+4.55%
6 months+41.54%
Current year+16.21%
More quotes
1 week
27.00
Extreme 27
29.50
1 month
27.00
Extreme 27
32.00
Current year
24.27
Extreme 24.2667
32.00
1 year
14.00
Extreme 14
32.00
3 years
8.68
Extreme 8.675
43.00
5 years
4.51
Extreme 4.5111
48.00
10 years
4.51
Extreme 4.5111
48.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 21-10-12
Founder 37 11-01-31
Founder 59 11-01-31
Members of the board TitleAgeSince
Director/Board Member 57 22-06-07
Founder 59 11-01-31
Founder 73 18-11-30
More insiders
Date Price Change Volume
24-04-17 27.6 +1.47% 1,292,553
24-04-16 27.2 -3.72% 1,771,474
24-04-15 28.25 -1.91% 2,161,935
24-04-12 28.8 -2.37% 1,072,264
24-04-11 29.5 +1.72% 937,421

Delayed Quote London S.E., April 17, 2024 at 11:35 am EDT

More quotes
hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO plc runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.276 GBP
Average target price
0.3607 GBP
Spread / Average Target
+30.69%
Consensus

Annual profits - Rate of surprise